Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan

References

• World Health Organization. HIV 2022 [October 18, 2022]. Available from: https://www.who.int/data/gho/data/themes/hiv-aids.
   Google Scholar
• Nishiura H. Estimating the incidence and diagnosed proportion of HIV infections in Japan: a statistical modeling study. PeerJ. 2019;7:e6275. doi: 10.7717/peerj.6275.
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases. HIV/AIDS in Japan. 2019. IASR. 2021;41:175–176.
   Google Scholar
• Biello KB, Mimiaga MJ, Santostefano CM, et al. MSM at highest risk for HIV acquisition express greatest interest and preference for injectable antiretroviral PrEP compared to daily, oral medication. AIDS Behav. 2018;22(4):1158–1164. doi: 10.1007/s10461-017-1972-6.
   PubMed Web of Science ®Google Scholar
• Takano M, Iwahashi K, Satoh I, et al. Assessment of HIV prevalence among MSM in Tokyo using self-collected dried blood spots delivered through the postal service. BMC Infect Dis. 2018;18(1):627. doi: 10.1186/s12879-018-3491-0.
   PubMedGoogle Scholar
• Gilmour S, Peng L, Li J, et al. New strategies for prevention of HIV among Japanese men who have sex with men: a mathematical model. Sci Rep. 2020;10(1):18187. doi: 10.1038/s41598-020-75182-7.
   PubMed Web of Science ®Google Scholar
• AIDS Prevention Information Network. Situation in Japan: Committee on AIDS Trends. Quarterly Report 2022 2022. Available from: https://api-net.jfap.or.jp/status/japan/index.html.
   Google Scholar
• Kimura H. Cost of HIV treatment in highly active antiretroviral therapy in Japan. Nihon Rinsho. 2002;60(4):813–816.
   PubMedGoogle Scholar
• World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015.
   Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599. doi: 10.1056/NEJMoa1011205.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 2012/08/02367(5):399–410. doi: 10.1056/NEJMoa1108524.
   PubMed Web of Science ®Google Scholar
• Mizushima D, Takano M, Ando N, et al. A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo. J Infect Chemother. 2022;28(6):762–766. doi: 10.1016/j.jiac.2022.02.013.
   PubMed Web of Science ®Google Scholar
• Cambiano V, Miners A, Dunn D, et al. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. Lancet Infect Dis. 2018;18(1):85–94. doi: 10.1016/S1473-3099(17)30540-6.
   PubMed Web of Science ®Google Scholar
• Nichols BE, Boucher CAB, van der Valk M, et al. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in The Netherlands: a mathematical modelling study. Lancet Infect Dis. 2016;16(12):1423–1429. Decdoi: 10.1016/S1473-3099(16)30311-5.
   PubMed Web of Science ®Google Scholar
• ten Brink DC, Martin-Hughes R, Minnery ME, et al. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in asia: a modelling study. PLoS One. 2022;17(5):e0268240. doi: 10.1371/journal.pone.0268240.
   PubMed Web of Science ®Google Scholar
• PrEPMAP. PrEP status by country [cited October 24, 2022]. Available from: https://www.prepmap.org/prep_status_by_country#japan.
   Google Scholar
• Ministry of Health LaW. Requests submitted in Part IV 2021. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000111297.html.
   Google Scholar
• Yamamoto N, Koizumi Y, Tsuzuki S, et al. Evaluating the cost-effectiveness of a pre-exposure prophylaxis program for HIV prevention for men who have sex with men in Japan. Sci Rep. 2022;12(1):3088. doi: 10.1038/s41598-022-07116-4.
   PubMed Web of Science ®Google Scholar
• Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5. Value Health. 2012;15(6):828–834. doi: 10.1016/j.jval.2012.06.011.
   PubMed Web of Science ®Google Scholar
• Center for Outcomes Research and Economic Evaluation for Health. Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council. (C2H) Nioph, editor. version 3.0 approved by CSIMC on 19th January, 2022; 2022. Available from: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf
   Google Scholar
• Research group on the system for providing pre-exposure and post-exposure prophylactic medication for HIV infection. Health, Labor and Welfare Science Research Grant. AIDS Policy Research Project “Questionnaire Survey on PrEP”. 2019.
   Google Scholar
• Statistics Bureau of Japan. Chapter 2 Population and Households 2017. Available from: https://www.stat.go.jp/english/data/nenkan/66nenkan/1431-02.html.
   Google Scholar
• Community centers in the Tokyo metropolitan area. Status of HIV/AIDS infection in Japan. 2013.
   Google Scholar
• Nishijima T, Inaba Y, Kawasaki Y, et al. Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan. AIDS. 2020;34(6):913–921. doi: 10.1097/QAD.0000000000002498.
   PubMed Web of Science ®Google Scholar
• Underhill K, Morrow KM, Colleran C, et al. Explaining the efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention: a qualitative study of message framing and messaging preferences among US men who have sex with men. AIDS Behav. 2016;20(7):1514–1526. Juldoi: 10.1007/s10461-015-1088-9.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences. Data on file. 2022.
   Google Scholar
• Higasa S, Kojima K, Masuda J. Basic survey for anti-HIV therapy and adherence to anti-HIV drug prescription trend survey at the start of treatment. O-C6-*. Annual Congress of the Japan Society for AIDS Research, et al. 2020.
   Google Scholar
• Japan National Health Insurance. Prescription fee 2022. Available from: https://www.mhlw.go.jp/content/12400000/000603756.pdf.
   Google Scholar
• Kato H, Kanou K, Arima Y, et al. The importance of accounting for testing and positivity in surveillance by time and place: an illustration from HIV surveillance in Japan. Epidemiol Infect. 2018;146(16):2072–2078. doi: 10.1017/S0950268818002558.
   PubMed Web of Science ®Google Scholar
• Asahata S, Imamura A, Yanagisawa Y, et al. A study on hospitalization of AIDS patients in the HAART era. JJapanese AIDS Soc. 2013;15:194–198.
   Google Scholar
• Hasegawa M, Komoto S, Shiroiwa T, et al. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43–51. doi: 10.1016/j.jval.2019.10.005.
   PubMed Web of Science ®Google Scholar
• UNAIDS. Prevailing against pandemics by putting people at the centre. 2020. Available from: https://www.unaids.org/sites/default/files/media_asset/prevailing-against-pandemics_en.pdf
   Google Scholar
• Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–536. doi: 10.1016/S0140-6736(06)69162-9.
   PubMed Web of Science ®Google Scholar
• Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med. 1997;44(9):1303–1312. doi: 10.1016/s0277-9536(96)00258-4.
   PubMed Web of Science ®Google Scholar
• Smith DK, Herbst JH, Zhang X, et al. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015; 168(3):337–344. doi: 10.1097/QAI.0000000000000461.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tanuma J, Li J, et al. Elimination of HIV transmission in Japanese MSM with combination interventions. Lancet Reg Health West Pac. 2022;23:100467. doi: 10.1016/j.lanwpc.2022.100467.
   PubMedGoogle Scholar
• Lamontagne E, Over M, Stover J. The economic returns of ending the AIDS epidemic as a public health threat. Health Policy. 2019;123(1):104–108. doi: 10.1016/j.healthpol.2018.11.007.
   PubMed Web of Science ®Google Scholar
• van Dijk M, de Wit JBF, Guadamuz TE, et al. Slow uptake of PrEP: behavioral predictors and the influence of price on PrEP uptake among MSM with a high interest in PrEP. AIDS Behav. 2021;25(8):2382–2390. doi: 10.1007/s10461-021-03200-4.
   PubMed Web of Science ®Google Scholar
• Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect. 2011;87(3):183–190. doi: 10.1136/sti.2010.047514.
   PubMed Web of Science ®Google Scholar
• Cannon C, Celum C. Sexually transmissible infection incidence in men who have sex with men using HIV pre-exposure prophylaxis in Australia. Lancet Infect Dis. 2022;22(8):1103–1105. doi: 10.1016/S1473-3099(22)00284-5.
   PubMed Web of Science ®Google Scholar
• Keen P, Hammoud MA, Bourne A, et al. Use of HIV pre-exposure prophylaxis (PrEP) associated with lower HIV anxiety among gay and bisexual men in Australia who are at high risk of HIV infection: results from the flux study. J Acquir Immune Defic Syndr. 2020;83(2):119–125. doi: 10.1097/QAI.0000000000002232.
   PubMed Web of Science ®Google Scholar
• Japan National Health Insurance. Price list 2022. Available from: https://www.mhlw.go.jp/content/12400000/000603751.pdf.
   Google Scholar
• National Center for Global Health and Medicine. Average cost of inpatient cases [September 28, 2022]. Available from: http://www.hosp.ncgm.go.jp/inpatient/070/index.html.
   Google Scholar
• Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193–1202. doi: 10.1016/j.jval.2021.03.010.
   PubMed Web of Science ®Google Scholar
• Miners A, Phillips A, Kreif N, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV. 2014;1(1):e32-40–e40. doi: 10.1016/S2352-3018(14)70018-9.
   PubMed Web of Science ®Google Scholar